Relmada Therapeutics, Inc. (RLMD) — Stock Score Summary

Relmada Therapeutics, Inc. (RLMD) has a MoatMap StockRank of 62/100 based on Quality (43/100), Value (32/100), and Momentum (72/100) factor scores. The current signal is HOLD. Relmada Therapeutics is a clinical-stage biotech company with binary trial risk. It lacks revenues, earnings, and a proven moat, making it entirely unsuitable for our quality-focused investment framework.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative treatments for central nervous system (CNS) disorders, primarily focusing on major depressive disorder (MDD) and neuropathic pain. The company's lead investigational compound, REL-1017, is a novel NMDA receptor modulator with the potential to offer a new approach for treating depression. Relmada operates as a niche biotech player with its pipeline concentrated on high-unmet-need CNS conditions.

Key Financial Metrics

Price$6.42
Market Cap$760M
P/E (Forward)-17.49
Price/Book6.08
Return on Equity-25.6%
Return on Invested Capital-67.5%
Debt/Equity0.10
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-8M

Relmada Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Relmada Therapeutics, Inc.’s (RLMD) StockRank?
MoatMap’s StockRank for Relmada Therapeutics, Inc. (RLMD) is 62/100, with a Hold signal. It is a composite of Quality (43), Value (32), and Momentum (72) factor ranks across MoatMap’s 19,000+ stock universe.
Does Relmada Therapeutics, Inc. have an economic moat?
Relmada Therapeutics, Inc. (RLMD) has a Quality factor score of 43/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Relmada Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Relmada Therapeutics, Inc. (RLMD) is Hold, based on a StockRank of 62/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Relmada Therapeutics, Inc. in?
Relmada Therapeutics, Inc. (RLMD) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksRLMD deep dive reportAI ChampionsHow we score stocksSense-check another stock